Trial Profile

A Study of RC48-ADC Combine With Toripalimab and Chemotherapy or RC48-ADC Combine With Toripalimab and Trastuzumab as First-line Treatment in Local Advanced or Metastatic Gastric Cancer With the HER2 Expression

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Disitamab vedotin (Primary) ; Oxaliplatin (Primary) ; Toripalimab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Sponsors RemeGen

02 Jun 2025 According to a RemeGen media release, data from this trial were presented in an oral presentation at the 2025 ASCO Annual Meeting.
02 Jun 2025 Results from the phase 2 part of this trial presented in the RemeGen media release.
20 Jan 2024 Planned number of patients changed from 60 to 90, as per Trial design, presented at the 2024 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com